Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.11779/1129
Title: Health Outcomes Among Patients Diagnosed With Schizophrenia in the Us Veterans Health Administration Population Who Transitioned From Once-Monthly To Once-Every Paliperidone Palmitate: an Observational Retrospective Analysis
Authors: Khouyr, Antoine El
Wang, Li
Joshi, Kruti
Patel, Charmi
Başer, Onur
Huang, Ahong
Keywords: Healthcare Costs
Schizophrenia
Medication Adherence
Antipsychotic Agents
Neurology
Paliperidone Palmitate
Publisher: Springer
Source: Patel, C., El, K. A., Huang, A., Wang, L., Baser, O., & Joshi, K. (August 08, 2019). Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis. Advances in Therapy. 1-13.
Abstract: There is limited literature on treatment patterns, healthcare resource utilization (HRU), and costs among patients who transition from once-monthly paliperidone palmitate (PP1M) to once-every-3-month paliperidone palmitate (PP3M) in a real-world setting. Hence, this study compared treatment patterns, HRU, and costs 12-month pre- and post-PP3M transition among Veteran’s Health Administration (VHA) patients with schizophrenia.
URI: https://doi.org/10.1007/s12325-019-01039-9
https://hdl.handle.net/20.500.11779/1129
ISSN: 1865-8652
0741-238X
Appears in Collections:Ekonomi Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

4
checked on Nov 9, 2024

WEB OF SCIENCETM
Citations

4
checked on Nov 9, 2024

Page view(s)

10
checked on Nov 4, 2024

Download(s)

10
checked on Nov 4, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.